Mineralys Therapeutics Dirección
Dirección controles de criterios 0/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Jon Congleton
Chief Executive Officer (CEO)
US$5.4m
Compensación total
| Porcentaje del salario del CEO | 9.7% |
| Permanencia del CEO | 4yrs |
| Participación del CEO | 1.8% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 2.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Oct 07
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Sep 17We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$91m |
| Dec 31 2023 | US$5m | US$517k | -US$72m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$2m | US$417k | -US$30m |
| Sep 30 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$675k | US$346k | -US$19m |
Compensación vs. Mercado: La compensación total de Jon($USD5.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.24M).
Compensación vs. Ingresos: La compensación de Jon ha aumentado mientras la empresa no es rentable.
CEO
Jon Congleton (61 yo)
4yrs
Permanencia
US$5,355,257
Compensación
Mr. Jon Congleton serves as Chief Executive Officer and Director at Mineralys Therapeutics, Inc. since November 2020. He serves as an Operating Partner at Catalys Pacific. He was the Chief Executive Office...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.5yrs | US$630.13k | sin datos | |
| CEO & Director | 4yrs | US$5.36m | 1.8% $ 12.1m | |
| CFO & Secretary | 2.7yrs | US$2.19m | 0.48% $ 3.2m | |
| Chief Medical Officer | 3.8yrs | US$2.35m | 0.27% $ 1.8m | |
| Executive Vice President of Operations | 1.8yrs | sin datos | sin datos | |
| Vice President of Human Resources | less than a year | sin datos | sin datos | |
| Senior Vice President of CMC | no data | sin datos | sin datos | |
| Senior Vice President of Quality Assurance | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Operations | 1.8yrs | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Clinical Development | less than a year | sin datos | sin datos |
1.8yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MLYS no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.5yrs | US$630.13k | sin datos | |
| CEO & Director | 4yrs | US$5.36m | 1.8% $ 12.1m | |
| Independent Director | 1.2yrs | US$427.02k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$607.30k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 1.2yrs | US$428.52k | 0% $ 0 | |
| Director | less than a year | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 2.5yrs | US$611.91k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos |
2.5yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de MLYS no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.